Canada’s Drug Agency Recommends Public Reimbursement of Lecanemab for Early Alzheimer’s Disease
Statements
Canada’s Drug Agency (CDA) has issued a final positive recommendation supporting public reimbursement of lecanemab (Leqembi®) for eligible people with early Alzheimer’s disease.
Lecanemab is a disease-modifying treatment that targets amyloid, a protein that builds up in the brains of people with Alzheimer’s disease. Health Canada approved lecanemab in 2025 for the treatment of early Alzheimer’s disease in appropriate patients.
CDA’s recommendation supports making lecanemab available through Canada’s public drug plans, subject to the conditions outlined in its recommendation. The decision follows an earlier draft recommendation that did not support public reimbursement.
The final recommendation represents an important step toward improving access to disease-modifying treatments for people living with early Alzheimer’s disease in Canada. The next steps will involve discussions with provincial and territorial drug plans about reimbursement and implementation.
Lecanemab is one of two recently approved disease-modifying Alzheimer’s treatments in Canada. Donanemab (Kisunla™) was approved by Health Canada in May 2026. Like lecanemab, donanemab targets amyloid and is intended for people in the early stages of Alzheimer’s disease. Donanemab is also undergoing the reimbursement review process in Canada.
